F. Zeevat

Faculteit Medische Wetenschappen/UMCG

Telefoon:

E-mail:

f.zeevat umcg.nl

ORCID Research Portal

Publicaties

Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands

Zeevat, F., van der Pol, S., Westra, T., Beck, E., Postma, M. J. & Boersma, C., mrt.-2025, In: Advances in therapy. 42, 3, blz. 1550-1569 20 blz., e13174.

Onderzoeksoutput › › peer review

Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection

Zeevat, F., van der Pol, S., Kieffer, A., Postma, M. J. & Boersma, C., mei-2025, In: Pharmacoeconomics. 43, 5, blz. 569-582 14 blz.

Onderzoeksoutput › › peer review

Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands

Zeevat, F., Luttjeboer, J., Korsten, K., van Boven, M., Postma, M. J., van der Pol, S. & Boersma, C., 24-okt.-2025, In: Vaccine. 65, 12 blz., 127735.

Onderzoeksoutput › › peer review

Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal

Pham, T. H., Mihajlović, J., Loncar, I., Cao, B. K., Zeevat, F., Pham, T. A., Wondimu, A., Meszaros, K. & van der Schans, J., 16-dec.-2025, (E-pub ahead of print) In: PharmacoEconomics - open.

Onderzoeksoutput › › peer review

Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations

van der Pol, S., Zeevat, F., Postma, M. J. & Boersma, C., 31-mei-2024, In: Vaccine. 42, 15, blz. 3429-3436 8 blz.

Onderzoeksoutput › › peer review

Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands: a Holistic Approach

Zeevat, F., Simons, J. J. M., Westra, T. A., Wilschut, J. C., Boersma, C. & Postma, M. J., mrt.-2024, In: Infectious Diseases and Therapy. 13, blz. 481–499 19 blz.

Onderzoeksoutput › › peer review

Assessment of vaccination policies from a health economic perspective: opportunities and emerging foci

Zeevat, F., 2023, [Groningen]: University of Groningen. 218 blz.

Onderzoeksoutput

Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older Adults

Zeevat, F., Wilschut, J. C., Boersma, C. & Postma, M. J., apr.-2023, In: Value in Health. 26, 4, blz. 461-464 5 blz.

Onderzoeksoutput › › peer review

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom

RESCEU Investigators, Zeevat, F., Luttjeboer, J., Paulissen, J. H. J., van der Schans, J., Beutels, P., Boersma, C. & Postma, M. J., 12-aug.-2022, In: The Journal of Infectious Diseases. 226, 1, blz. S102-S109 8 blz.

Onderzoeksoutput › › peer review

Reply to Anglemyer et al

Zeevat, F., Boersma, C. & Postma, M., 1-mei-2022, In: Journal of infectious diseases. 225, 9, blz. 1682-1682 1 blz., 621.

Onderzoeksoutput › › peer review

Alle (16) publicaties

Bekijk volledig onderzoeksprofiel

F. Zeevat

Publicaties

Functioneel

Standaard

Volledig